0000950170-24-044840.txt : 20240416
0000950170-24-044840.hdr.sgml : 20240416
20240416165911
ACCESSION NUMBER: 0000950170-24-044840
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240414
FILED AS OF DATE: 20240416
DATE AS OF CHANGE: 20240416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Guillaudeux Thierry
CENTRAL INDEX KEY: 0001958094
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 24848533
MAIL ADDRESS:
STREET 1: C/O KINETA, INC.
STREET 2: 219 TERRY AVE. N., SUITE 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KINETA, INC./DE
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7683 SE 27TH STREET
STREET 2: SUITE 481
CITY: MERCER ISLAND
STATE: WA
ZIP: 98040
BUSINESS PHONE: (206) 378-0400
MAIL ADDRESS:
STREET 1: 7683 SE 27TH STREET
STREET 2: SUITE 481
CITY: MERCER ISLAND
STATE: WA
ZIP: 98040
FORMER COMPANY:
FORMER CONFORMED NAME: YUMANITY THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20201223
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140813
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
4
1
ownership.xml
4
X0508
4
2024-04-14
0001445283
KINETA, INC./DE
KA
0001958094
Guillaudeux Thierry
C/O KINETA, INC.
7683 SE 27TH STREET, SUITE 481
MERCER ISLAND
WA
98040
false
true
false
false
Chief Scientific Officer
false
Stock Option (Right to Buy)
0.36
2024-04-14
4
A
false
225000
0
A
2024-04-13
Common Stock
225000
225000
D
25% of the shares are vested and exercisable upon the grant, 25% of the shares will vest and become exercisable over the 36 month period following the award on the one-month anniversary of the vesting commencement date subject to the reporting person's continuous service status through each vesting date, and 50% of the shares will vest and become exercisable subject to the achievement of a Transaction or Qualified Transaction.
Footnote 2 is a continuation of Footnote 1: A "Qualified Transaction" is defined as either (i) a capital raise commitment of greater than $25 million with a minimum of $10 million upon closing or (ii) a partnership event resulting in an upfront cash payment to the Company of at least $15 million with future milestones of greater than $100 million (in cash and equity). In the event the Board of Directors of the Company approves a transaction that does not meet the criteria of a Qualified Transaction, it shall be deemed a "Transaction". In the event of the Qualified Transaction, all such shares shall immediately become fully vested and exercisable. In the event of a Transaction, all shares shall vest in an equal monthly number such that the shares will be vested and exercisable in full 36 months following the award date.
/s/ Thierry Guillaudeux
2024-04-16